X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (204337) 204337
Newspaper Article (6310) 6310
Newsletter (4570) 4570
Book Chapter (1013) 1013
Magazine Article (938) 938
Transcript (323) 323
Book / eBook (288) 288
Web Resource (176) 176
Conference Proceeding (102) 102
Dissertation (93) 93
Trade Publication Article (62) 62
Publication (49) 49
Streaming Video (45) 45
Government Document (38) 38
Book Review (31) 31
Reference (22) 22
Report (13) 13
Journal / eJournal (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (151791) 151791
female (75373) 75373
animals (63715) 63715
male (63607) 63607
antibodies (44320) 44320
antibodies, monoclonal - therapeutic use (41728) 41728
middle aged (41612) 41612
adult (41378) 41378
immunology (34703) 34703
mice (33055) 33055
oncology (28464) 28464
aged (27591) 27591
treatment outcome (24151) 24151
monoclonal antibodies (23340) 23340
cancer (21670) 21670
proteins (18749) 18749
research (16698) 16698
medicine, research & experimental (16235) 16235
immunotherapy (16136) 16136
health aspects (15795) 15795
therapy (15731) 15731
care and treatment (15391) 15391
pharmacology & pharmacy (15036) 15036
analysis (14864) 14864
expression (13928) 13928
monoclonal-antibody (13416) 13416
adolescent (13363) 13363
viral antibodies (13177) 13177
antigens (12995) 12995
antibodies, monoclonal, humanized (12736) 12736
vaccines (12331) 12331
antineoplastic agents - therapeutic use (12269) 12269
hematology (11701) 11701
antibodies, monoclonal, humanized - therapeutic use (11359) 11359
immunoglobulins (10973) 10973
rituximab (10902) 10902
antibody (10471) 10471
chemotherapy (10454) 10454
disease (10236) 10236
child (10158) 10158
rheumatology (10148) 10148
research article (10027) 10027
antineoplastic combined chemotherapy protocols - therapeutic use (10006) 10006
medical research (9943) 9943
immunosuppressive agents - therapeutic use (9939) 9939
tumors (9733) 9733
medicine & public health (9429) 9429
medicine (9296) 9296
transplantation (9089) 9089
antibodies, monoclonal - administration & dosage (9034) 9034
enzyme-linked immunosorbent assay (9034) 9034
time factors (9011) 9011
drug therapy (8879) 8879
infliximab (8861) 8861
multidisciplinary sciences (8817) 8817
aged, 80 and over (8749) 8749
patients (8681) 8681
infections (8637) 8637
retrospective studies (8610) 8610
clinical trials (8609) 8609
antibodies, monoclonal - adverse effects (8596) 8596
surgery (8465) 8465
prognosis (8377) 8377
risk factors (8320) 8320
mice, inbred balb c (8307) 8307
young adult (8252) 8252
inflammation (8137) 8137
immunization (8101) 8101
disease models, animal (7955) 7955
vaccination (7924) 7924
cell biology (7890) 7890
infection (7851) 7851
diagnosis (7720) 7720
antibodies, monoclonal - immunology (7712) 7712
cytokines (7653) 7653
apoptosis (7615) 7615
studies (7606) 7606
rats (7551) 7551
cell line, tumor (7518) 7518
cells (7484) 7484
infectious diseases (7439) 7439
lymphocytes (7361) 7361
efficacy (7258) 7258
monoclonal-antibodies (7258) 7258
biochemistry & molecular biology (7097) 7097
follow-up studies (7079) 7079
abridged index medicus (7063) 7063
medicine, general & internal (7056) 7056
bevacizumab (7049) 7049
gene expression (6996) 6996
fluorescent antibody technique (6920) 6920
biotechnology & applied microbiology (6891) 6891
double-blind (6834) 6834
safety (6760) 6760
allergy and immunology (6718) 6718
clinical trials as topic (6623) 6623
immunohistochemistry (6620) 6620
antibodies, monoclonal - pharmacology (6333) 6333
flow cytometry (6280) 6280
t cells (6236) 6236
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (138) 138
Online Resources - Online (136) 136
Collection Dvlpm't (Acquisitions) - Vendor file (19) 19
Collection Dvlpm't (Acquisitions) - Closed Orders (14) 14
UofT at Mississauga - Stacks (10) 10
Engineering & Comp. Sci. - Stacks (9) 9
New College (Ivey) - Stacks (5) 5
Robarts - Stacks (5) 5
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
UofT at Scarborough - Stacks (3) 3
OISE - Processing (2) 2
UTL at Downsview - May be requested (2) 2
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Closed Orders (1) 1
Gerstein Science - Missing (1) 1
Gerstein Science - Periodical Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Trinity College (John W Graham) - Periodical Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (208405) 208405
Japanese (2287) 2287
German (2250) 2250
French (2151) 2151
Russian (1291) 1291
Spanish (1001) 1001
Chinese (753) 753
Italian (416) 416
Polish (366) 366
Dutch (179) 179
Hungarian (157) 157
Czech (134) 134
Portuguese (124) 124
Danish (121) 121
Korean (55) 55
Romanian (54) 54
Finnish (53) 53
Swedish (50) 50
Hebrew (46) 46
Norwegian (44) 44
Croatian (41) 41
Ukrainian (40) 40
Bulgarian (38) 38
Turkish (30) 30
Slovak (24) 24
Serbian (23) 23
Arabic (7) 7
Lithuanian (5) 5
Icelandic (3) 3
Afrikaans (2) 2
Bosnian (2) 2
Slovenian (2) 2
Greek (1) 1
Hindi (1) 1
Ndonga (1) 1
Persian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 2, pp. 175 - 187
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 475 - 496
Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with... 
Biologic response modifiers | Systemic lupus erythematosus | Vasculitis | Disease-modifying antirheumatic drugs | Biologics | Rheumatoid arthritis | SYSTEMIC-LUPUS-ERYTHEMATOSUS | RITUXIMAB THERAPY | 5-AMINOSALICYLIC ACID | REFRACTORY NEUROSARCOIDOSIS | ADENOSINE RECEPTORS | MEDICINE, GENERAL & INTERNAL | TUMOR-NECROSIS-FACTOR | COMBINATION TREATMENT | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | MYCOPHENOLATE-MOFETIL | Hydroxychloroquine - therapeutic use | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Certolizumab Pegol | Rheumatic Diseases - drug therapy | Colchicine - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Cyclophosphamide - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Infliximab | Minocycline - therapeutic use | Immunoconjugates - therapeutic use | Antirheumatic Agents - therapeutic use | Rheumatic Diseases - immunology | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin G - therapeutic use | Rituximab | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Isoxazoles - therapeutic use | Adalimumab | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Tumor Necrosis Factors - antagonists & inhibitors
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, p. CD012657
Journal Article